There appears to be alot of emotional posts on the obj threads of late and as witnessed by a rollercoaster sp in the past month(s)this is perhaps understandable. However for the benefit of the new posters/holders I would like to share just some facts of the past year.
There are many more facts so i advise to please DYOR and always take what you read on this forum with a grain of salt (Incl this post)
OBJ's technologies utilise magnetic field and magnetic array processes to enhance the delivery of therapeutic and beneficial compounds. OBJ's technologies have been shown in multi-centred university studies and independent commercial evaluations to enhance transdermal drug delivery of a wide a wide range of commercially significant drugs and peptides.
Last July Australian studies proved the eM-Patch technology increased penetration of area by over 20 fold at the 30 to 40 minute points and by almost 7 fold after one hour of application. This result is consistent with the 8 fold increase in hydration related measures observed in human volunteers in the previous OCT study. The combined in vivo in vitro study demonstrated the ability for the eM-Patch system to provide greater cosmetic effects earlier and with less time commitment from consumers and the patient, all of which are believed to be important commercial benefits of the eM-Patch technology.
Last October re US STUDY RESULTS OBJ advised that they had received the final report from Azopharma covering the companys research collaboration with a global FMCG company. The report by Azopharma Contract Services Inc, a GLP/GMP accredited contract research organisation in Miami Florida, set out the results of an eight-month patch development and evaluation program. The study tested the delivery performance of OBJs dermaportation and ETP technologies in a fully formulated patch format, when compared to an existing Over the Counter (OTC) drug product with significant international sales.
OBJ had previously advised the market that it had entered into an Agreement with a major international FMCG company to evaluate OBJs two main technologies and had engaged Azopharma Contract Services Inc as the independent Contract Research Organisation (CRO) to undertake the formulation and evaluation phases. The FMCG companys stated objective in the Agreement with OBJ was to achieve up to a 10- fold increase in drug delivery over an existing commercial product. Under the terms of the Agreement, OBJ was and still is restricted from disclosing any information relating to the drug tested, the comparative product or the market.
Last November obj advise that it has entered into a MTA with 3M, for the evaluation of the Companys eM-patch technologies as an approach to enhance transdermal drug delivery. 3M is an American multinational corporation with 79,000 employees operating in 60 countries generating global sales in excess of US$25 billion in 2008. The evaluation was conducted by the 3M Drug Delivery Systems division which has been a leader in drug delivery for more than 50 years and has extensive expertise in toxicology, regulatory, manufacturing, quality assurance and operations. The Materials Transfer Agreement sets the parameters for an initial in vitro testing program to evaluate the performance of the eM-patch technology in conjunction with 3M drug delivery platforms and proprietary formulations. The evaluation program was to be completed by 1st April 2010.
We can continue to speculate over wording in past anns, charts or negative/positive sentiments however these cold hard facts still remain
FYI I have also spent many hours over the past month researching similar (other companies) technologies that are currently being tested by 3M or GSK, and I have found to date.... NOT ONE!
(20min delay)